David M. Mott

This profile gathers the share dealings of David M. Mott across 5 companies, led by Ardelyx, Inc., Epizyme, Inc. and Mersana Therapeutics, Inc. In total, 42 filings cover trades dated from 12 January 2016 to 16 June 2026.

Both buying and selling appear: 16 purchases worth €8.9M, against 1 sale worth €1.2M. The totals do not cover 3 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 18 share grants and 5 option exercises. Since January 2026: 1 purchase and no sales on the market.

Half of the purchases are above €645k and half below. The 16 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The record was last updated on 18 June 2026 with a share grant in Ardelyx, Inc. The clock since the last published purchase (23 February 2026) now reads 237 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.